These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 33693297)

  • 21. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
    Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
    Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension.
    Martynyuk TV; Nakonechnikov SN; Chazova IY
    Ter Arkh; 2018 Apr; 90(4):72-80. PubMed ID: 30701878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
    Martynyuk TV; Aleevskaya AM
    Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension].
    Moiseeva OM; Rudakova AV
    Ter Arkh; 2017; 89(3):72-77. PubMed ID: 28378734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.
    Jansa P; Pulido T
    Am J Cardiovasc Drugs; 2018 Feb; 18(1):1-11. PubMed ID: 29280064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.
    Wang S; Yu M; Zheng X; Dong S
    Drug Deliv; 2018 Nov; 25(1):1898-1909. PubMed ID: 30442035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of macitentan for the treatment of pulmonary arterial hypertension.
    Selej M; Romero AJ; Channick RN; Clozel M
    Ann N Y Acad Sci; 2015 Nov; 1358():68-81. PubMed ID: 26291180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension.
    Krause A; Zisowsky J; Dingemanse J
    Pulm Pharmacol Ther; 2018 Apr; 49():140-146. PubMed ID: 29501590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world effectiveness and safety of macitentan in patients with pulmonary artery hypertension: a multicenter, retrospective, observational study in China.
    Chen YC; Dai HL; Liu CL; Li J; Ji QS; Cao YS; Xiao J; Jian R; Zhuo JM; Luo XC; Gu H
    Curr Med Res Opin; 2024 Jul; ():1-15. PubMed ID: 39044676
    [No Abstract]   [Full Text] [Related]  

  • 30. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities.
    McLaughlin VV; Sitbon O; Chin KM; Galiè N; Hoeper MM; Kiely DG; MacDonald G; Martin N; Mathai SC; Peacock A; Tawakol A; Torbicki A; Noordegraaf AV; Rosenkranz S
    Eur J Heart Fail; 2024 Jul; ():. PubMed ID: 38966990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacotherapy for pulmonary arterial hypertension.
    Parikh V; Bhardwaj A; Nair A
    J Thorac Dis; 2019 Sep; 11(Suppl 14):S1767-S1781. PubMed ID: 31632754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Targets in a High-Altitude Pulmonary Hypertension Rat Model Based on RNA-seq and Proteomics.
    Xu X; Li H; Wei Q; Li X; Shen Y; Guo G; Chen Y; He K; Liu C
    Front Med (Lausanne); 2021; 8():742436. PubMed ID: 34805208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-month follow-up.
    Jariwala P; Maturu VN; Jadhav KP; Punjani A; Boorugu H
    Lung India; 2022; 39(1):12-15. PubMed ID: 34975047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
    Rosenkranz S; Ghofrani HA; Beghetti M; Ivy D; Frey R; Fritsch A; Weimann G; Saleh S; Apitz C
    Heart; 2015 Nov; 101(22):1792-9. PubMed ID: 26135803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selexipag for the treatment of pulmonary arterial hypertension.
    Noel ZR; Kido K; Macaulay TE
    Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
    Channick RN; Delcroix M; Ghofrani HA; Hunsche E; Jansa P; Le Brun FO; Mehta S; Pulido T; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A; Galiè N
    JACC Heart Fail; 2015 Jan; 3(1):1-8. PubMed ID: 25457902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension.
    Steriade A; Seferian A; Jaïs X; Savale L; Jutant EM; Parent F; Sitbon O; Humbert M; Simonneau G; Montani D
    Ther Adv Respir Dis; 2014 Jun; 8(3):84-92. PubMed ID: 24728960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selexipag: A Review in Pulmonary Arterial Hypertension.
    Duggan ST; Keam SJ; Burness CB
    Am J Cardiovasc Drugs; 2017 Feb; 17(1):73-80. PubMed ID: 27988834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Macitentan for the treatment of pulmonary arterial hypertension.
    Hong IS; Coe HV; Catanzaro LM
    Ann Pharmacother; 2014 Apr; 48(4):538-47. PubMed ID: 24458948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.